Procalcitonin for guidance of antibiotic therapy

References

• Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J. Clin. Endocrinol. Metab.86(1), 396–404 (2001).
   PubMed Web of Science ®Google Scholar
• Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis.181(1), 176–180 (2000).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Muller B. Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Med. Wkly135(31–32), 451–460 (2005).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur. Respir. J.30(3), 556–573 (2007).
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology146(6), 2699–2708 (2005).
   PubMed Web of Science ®Google Scholar
• Haeuptle J, Zaborsky R, Fiumefreddo R et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur. J. Clin. Microbiol. Infect. Dis.28(1), 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit. Care Med.34(10), 2596–2602 (2006).
   PubMed Web of Science ®Google Scholar
• Muller B, Peri G, Doni A et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J. Leukoc. Biol.72(4), 643–649 (2002).
   PubMed Web of Science ®Google Scholar
• Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am. J. Respir. Crit. Care Med.164(3), 396–402 (2001).
   PubMed Web of Science ®Google Scholar
• de Kruif MD, Lemaire LC, Giebelen IA et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med.34(3), 518–522 (2008).
   PubMed Web of Science ®Google Scholar
• Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect. Dis.7, 137 (2007).
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A, Kolopp-Sarda MN et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit. Care Med.33(4), 792–796 (2005).
   PubMed Web of Science ®Google Scholar
• Muller B, Gencay MM, Gibot S et al. Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. Crit. Care Med.35(3), 990–991 (2007).
   PubMedGoogle Scholar
• Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest108(5), 1288–1291 (1995).
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Tomasso L, Dolan TF Jr. Predicting fever response of children with pneumonia treated with antibiotics. Clin. Pediatr.19(11), 753–760 (1980).
   PubMed Web of Science ®Google Scholar
• Muller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis.7, 10 (2007).
   PubMed Web of Science ®Google Scholar
• van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. Br. Med. J. (Clin. Res. Ed.)331(7507), 26 (2005).
   PubMed Web of Science ®Google Scholar
• Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis.39(2), 206–217 (2004).
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N. Engl. J. Med.350(5), 451–458 (2004).
   PubMed Web of Science ®Google Scholar
• Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit. Care Med.26(6), 1001–1006 (1998).
   PubMed Web of Science ®Google Scholar
• Becker KL, Nylen ES, Snider RH, Muller B, White JC. Immunoneutralization of procalcitonin as therapy of sepsis. J. Endotoxin Res.9(6), 367–374 (2003).
   PubMedGoogle Scholar
• Wagner KE, Martinez JM, Vath SD et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit. Care Med.30(10), 2313–2321 (2002).
   PubMed Web of Science ®Google Scholar
• Martinez JM, Wagner KE, Snider RH et al. Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg. Infect. (Larchmt)2(3), 193–202; discussion 202–193 (2001).
   PubMedGoogle Scholar
• Canale DD, Donabedian RK. Hypercalcitoninemia in acute pancreatitis. J. Clin. Endocrinol. Metab.40(4), 738–741 (1975).
   PubMed Web of Science ®Google Scholar
• Chesney RW, McCarron DM, Haddad JG et al. Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J. Lab. Clin. Med.101(4), 576–585 (1983).
   PubMedGoogle Scholar
• Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet341(8844), 515–518 (1993).
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med.138(1), W1–W12 (2003).
   PubMed Web of Science ®Google Scholar
• Bachmann LM, Juni P, Reichenbach S, Ziswiler HR, Kessels AG, Vogelin E. Consequences of different diagnostic ‘gold standards’ in test accuracy research: Carpal Tunnel Syndrome as an example. Int. J. Epidemiol.34(4), 953–955 (2005).
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Evaluation of fever in the patient with cancer. Eur. J. Cancer Clin. Oncol.25(Suppl. 2), S9–S16 (1989).
   PubMedGoogle Scholar
• Muller B, Becker KL, Schachinger H et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit. Care Med.28(4), 977–983 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall JC. Sepsis: rethinking the approach to clinical research. J. Leukoc. Biol.83(3), 471–482 (2008).
   PubMed Web of Science ®Google Scholar
• Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin. Trials2(3), 209–217 (2005).
   PubMed Web of Science ®Google Scholar
• Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit. Care Med.34(7), 1996–2003 (2006).
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect. Dis.7(3), 210–217 (2007).
   PubMed Web of Science ®Google Scholar
• Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann. Emerg. Med.50(1), 34–41 (2007).
   PubMed Web of Science ®Google Scholar
• Nylen ES, Muller B, Becker KL, Snyder RH. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin. Infect. Dis.36, 823–824 (2003).
   PubMed Web of Science ®Google Scholar
• Steinbach G, Rau B, Debard AL et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin. Chem. Lab. Med.42(4), 440–449 (2004).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Huber AR, Muller B. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor(R) and VIDAS(R) automated immunoassays. Clin. biochem.43(3), 341–344 (2009).
   PubMedGoogle Scholar
• Hubl W, Krassler J, Zingler C et al. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin. Lab.49(7–8), 319–327 (2003).
   PubMedGoogle Scholar
• de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M. Comparison of a new procalcitonin assay from roche with the established method on the BRAHMS kryptor. Clin. Chem.55(5), 1043–1044 (2009).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet363(9409), 600–607 (2004).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med.174(1), 84–93 (2006).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Wolbers M et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv. Res.7, 102 (2007).
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am. J. Respir. Crit. Care Med.177(5), 498–505 (2008).
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet375(9713), 463–474 (2010).
   PubMed Web of Science ®Google Scholar
• Hochreiter M, Kohler T, Schweiger AM et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit. Care13(3), R83 (2009).
   PubMed Web of Science ®Google Scholar
• Wipf JE, Lipsky BA, Hirschmann JV et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch. Intern. Med.159(10), 1082–1087 (1999).
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest131(1), 9–19 (2007).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Wolbers M et al. Effect of procalcitonin-based guidelines compared to standard guidelines on antibiotic use in lower respiratory tract infections: the Randomized-Controlled Multicenter ProHOSP Trial. JAMA302(10), 1059–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med.336(4), 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Kristoffersen KB, Sogaard OS, Wejse C et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission – a randomized trial. Clin. Microbiol. Infect.15(5), 481–487 (2009).
   PubMed Web of Science ®Google Scholar
• Lee RW, Lindstrom ST. A teaching hospital’s experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology12(5), 754–758 (2007).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Batschwaroff M, Dusemund F et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur. J. Clin. Microbiol. Infect. Dis.29(3), 269–277 (2009).
   PubMedGoogle Scholar
• Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet359(9318), 1648–1654 (2002).
   PubMed Web of Science ®Google Scholar
• Poses RM, Cebul RD, Wigton RS. You can lead a horse to water – improving physicians’ knowledge of probabilities may not affect their decisions. Med. Decis. Making15(1), 65–75 (1995).
   PubMed Web of Science ®Google Scholar
• Briel M, Langewitz W, Tschudi P, Young J, Hugenschmidt C, Bucher HC. Communication training and antibiotic use in acute respiratory tract infections. A cluster randomised controlled trial in general practice. Swiss Med. Wkly136(15–16), 241–247 (2006).
   PubMed Web of Science ®Google Scholar
• Briel M, Christ-Crain M, Young J et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam. Pract.6, 34 (2005).
   PubMedGoogle Scholar
• Briel M, Schuetz P, Mueller B et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch. Intern. Med.168(18), 2000–2007; discussion 2007–2008 (2008).
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Ewig S, Haagen U et al. A simple procalcitonin-guided strategy results in safe reductions of antibiotic use in patients with symptoms of acute respiratory tract infections in primary care. Eur. Respir. J. (2010) (In Press).
   PubMedGoogle Scholar
• Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. Br. Med. J. (Clin. Res. Ed.)338, b1374 (2009).
   PubMed Web of Science ®Google Scholar
• Stolz D, Smyrnios N, Eggimann P et al. Procalcitonin for reduced antibiotic exposure in ventilator associated pneumonia – a randomized study. Eur. Respir. J.34(6), 1364–1375 (2009).
   PubMed Web of Science ®Google Scholar
• Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg. Infect. Dis.10(3), 514–517 (2004).
   PubMed Web of Science ®Google Scholar
• Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection37(5), 432–437 (2009).
   PubMedGoogle Scholar
• Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect. Dis.1(4), 251–261 (2001).
   PubMedGoogle Scholar
• Nasrin D, Collignon PJ, Roberts L, Wilson EJ, Pilotto LS, Douglas RM. Effect of β lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. Br. Med. J. (Clin. Res. Ed.)324(7328), 28–30 (2002).
   PubMed Web of Science ®Google Scholar
• Dagan R, Barkai G, Givon-Lavi N et al. Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J. Infect. Dis.197(8), 1094–1102 (2008).
   PubMed Web of Science ®Google Scholar
• Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med.337(7), 441–446 (1997).
   PubMed Web of Science ®Google Scholar
• Reed SD, Laxminarayan R, Black DJ, Sullivan SD. Economic issues and antibiotic resistance in the community. Ann. Pharmacother.36(1), 148–154 (2002).
   PubMedGoogle Scholar
• Mueller F, Christ-Crain M, Bregenzer T et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest (2010) (In Press).
   PubMedGoogle Scholar
• Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection36(5), 396–407 (2008).
   PubMed Web of Science ®Google Scholar
• Hunziker S, Hugle T, Schuchardt K et al. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J. Bone Joint Surg.92(1), 138–148 (2010).
   PubMed Web of Science ®Google Scholar
• Hugle T, Schuetz P, Mueller B et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin. Exp. Rheumatol.26(3), 453–456 (2008).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection35(5), 352–355 (2007).
   PubMed Web of Science ®Google Scholar
• Marc E, Menager C, Moulin F et al. [Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak]. Arch. Pediatr.9(4), 358–364 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller C, Christ-Crain M, Muller B. What cardiologists do need to know about procalcitonin. Clin. Lab.51(1–2), 1–4 (2005).
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Papassotiriou J et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir. Res.10, 65 (2009).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Affolter B, Hunziker S, Balestra G, Hunziker P, Marsch P. Procalcitonin, CRP and white blood cell levels following hypothermia after cardiac arrest. Eur. J. Clin. Invest. (2010) (In press).
   PubMedGoogle Scholar
• Jensen JU, Lundgren B, Hein L et al. The Procalcitonin and Survival Study (PASS) – a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-active diagnostic and therapeutic responses to abnormal procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infect. Dis.8, 91 (2008).
   PubMed Web of Science ®Google Scholar
• Jensen J, Hein L, Bestle M et al. Efficacy and safety of procalcitonin (PCT) guided antimicrobial chemotherapy (AMC) in the intensive care unit (ICU): final results from a randomised controlled trial of 1,200 patients. Presented at: 47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA, USA, October 29–November 1 2009.
   Google Scholar
• Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med.32(3), 469–472 (2006).
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Marre R et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J.31(2), 349–355 (2008).
   PubMed Web of Science ®Google Scholar
• Huang DT, Weissfeld LA, Kellum JA et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann. Emerg. Med.52(1), 48–58, e42 (2008).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med.343(26), 1917–1924 (2000).
   PubMed Web of Science ®Google Scholar